IMMUNIC Files 8-K on Financial Condition and Operations
Ticker: IMUX · Form: 8-K · Filed: Feb 22, 2024 · CIK: 1280776
| Field | Detail |
|---|---|
| Company | Immunic, INC. (IMUX) |
| Form Type | 8-K |
| Filed Date | Feb 22, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, operations, 8-K
TL;DR
**IMMUNIC just dropped an 8-K, likely routine financial and operational updates, nothing wild.**
AI Summary
IMMUNIC, INC. filed an 8-K on February 22, 2024, reporting on its results of operations and financial condition, as well as other events and financial statements. The company, based in New York, NY, with IRS Employer Identification No. 56-2358443, operates in the pharmaceutical preparations industry. This filing indicates a routine disclosure of financial and operational updates.
Why It Matters
This filing provides investors with current information on IMMUNIC's financial health and operational status, which is crucial for making informed investment decisions.
Risk Assessment
Risk Level: low — The 8-K filing appears to be a standard disclosure of financial and operational information without indicating any specific adverse events.
Key Players & Entities
- IMMUNIC, INC. (company) — Registrant
- Delaware (other) — State of incorporation
- 001-36201 (other) — Commission File Number
- 56-2358443 (other) — IRS Employer Identification No.
- February 22, 2024 (date) — Date of earliest event reported
FAQ
What is the purpose of this 8-K filing by IMMUNIC, INC.?
The 8-K filing by IMMUNIC, INC. on February 22, 2024, is to report on its results of operations and financial condition, as well as other events and financial statements and exhibits, as per Item Information.
What is the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 22, 2024.
Where is IMMUNIC, INC.'s principal executive office located?
IMMUNIC, INC.'s principal executive office is located at 1200 Avenue of the Americas, Suite 200, New York, NY 10036 USA.
What is IMMUNIC, INC.'s IRS Employer Identification Number?
IMMUNIC, INC.'s IRS Employer Identification Number is 56-2358443.
What is the company's former name, if any, mentioned in the filing?
The company's former name was VITAL THERAPIES INC, with the name change date being 20040219.
Filing Stats: 554 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-02-22 06:35:56
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 IMUX The Nasdaq Stock Market LLC In
Filing Documents
- e619294_8k-immunic.htm (8-K) — 20KB
- e619294_ex99-1.htm (EX-99.1) — 67KB
- e619294_ex99-2.htm (EX-99.2) — 14KB
- image_001.jpg (GRAPHIC) — 4KB
- slide1.jpg (GRAPHIC) — 281KB
- slide2.jpg (GRAPHIC) — 329KB
- slide3.jpg (GRAPHIC) — 76KB
- slide4.jpg (GRAPHIC) — 47KB
- slide5.jpg (GRAPHIC) — 222KB
- slide6.jpg (GRAPHIC) — 153KB
- slide7.jpg (GRAPHIC) — 152KB
- slide8.jpg (GRAPHIC) — 201KB
- slide9.jpg (GRAPHIC) — 210KB
- slide10.jpg (GRAPHIC) — 220KB
- slide11.jpg (GRAPHIC) — 190KB
- slide12.jpg (GRAPHIC) — 42KB
- slide13.jpg (GRAPHIC) — 185KB
- slide14.jpg (GRAPHIC) — 42KB
- slide15.jpg (GRAPHIC) — 154KB
- slide16.jpg (GRAPHIC) — 36KB
- slide17.jpg (GRAPHIC) — 40KB
- slide18.jpg (GRAPHIC) — 118KB
- slide19.jpg (GRAPHIC) — 121KB
- 0001193805-24-000257.txt ( ) — 4174KB
- imux-20240222.xsd (EX-101.SCH) — 3KB
- imux-20240222_lab.xml (EX-101.LAB) — 33KB
- imux-20240222_pre.xml (EX-101.PRE) — 22KB
- e619294_8k-immunic_htm.xml (XML) — 4KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition On February 22, 2024, Immunic, Inc. (the "Company") issued a press release, a copy of which is furnished herewith as Exhibit 99.1, announcing the Company's financial results for the quarter and year ended December 31, 2023 and providing a corporate update (the "Press Release"). The information contained in Item 2.02 of this Current Report on Form 8-K, including the Press Release, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. In addition, this information shall not be deemed incorporated by reference into any of the Company's filings with the Securities and Exchange Commission, except as shall be expressly set forth by specific reference in any such filing.
01. Other Events
Item 8.01. Other Events On February 22, 2024, the Company posted an updated presentation on its website. A copy of the presentation is filed herewith as Exhibit 99.2 and is incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits Exhibit Description 99.1 Press Release, dated February 22, 2024 99.2 Presentation, dated February 22, 2024 104 Cover Page to this Current Report on Form 8-K in Inline XBRL
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. Dated: February 22, 2024 Immunic, Inc. By: /s/ Daniel Vitt Daniel Vitt Chief Executive Officer